People affected by diabetes mellitus (DM), chronic kidney disease (CKD), or heart failure are often prescribed sodium-glucose cotransporter-2 inhibitors (SGLT2is) as a method of treatment. This evidence concerns the gene SLC5A2 and chronic kidney disease.